Loading…
Neurogene Inc. is projected to rise to $35.13 by 2027, a +31% move from its current price of $26.87. NGNE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $25.97 | $26.89 | $27.84 | +0.07% |
| May 30 | $25.62 | $26.91 | $28.26 | +0.13% |
| May 31 | $25.35 | $26.92 | $28.59 | +0.20% |
| Jun 1 | $25.14 | $26.94 | $28.88 | +0.27% |
| Jun 2 | $24.95 | $26.96 | $29.13 | +0.33% |
| Jun 3 | $24.78 | $26.98 | $29.37 | +0.40% |
| Jun 4 | $24.63 | $27.00 | $29.59 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.63 | $27.00 | $29.59 | +0.47% |
| Week 2 | $23.82 | $27.12 | $30.88 | +0.93% |
| Week 3 | $23.24 | $27.25 | $31.94 | +1.40% |
| Week 4 | $22.78 | $27.37 | $32.89 | +1.88% |
| Week 5 | $22.40 | $27.50 | $33.77 | +2.35% |
| Week 6 | $22.07 | $27.63 | $34.60 | +2.83% |
| Week 7 | $21.77 | $27.76 | $35.39 | +3.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurogene Inc. is a clinical stage biotechnology company that develops genetic medicines for rare neurological diseases. Its product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
The company has license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
This concise profile focuses on the public information available for Neurogene Inc. and its clinical program scope, indicating the nature of its work and collaborations that shape its pipeline trajectory.
The description reflects the company’s positioning in the healthcare sector, highlighting its stage of development and foundational corporate details without extrapolating beyond the stated facts.
Neurogene Inc. (NGNE) is a biotechnology company with a market presence and a target niche in genetic medicines for rare neurological diseases. The current price is $27.71 and the market capitalization is $437.87M, with a market ranking of 3138.
The stock’s price outlook, as represented by the long-range forecast, shows a path of continued growth through 2050, with the 2026 average price aligned with today’s level at $27.71 and a projected rise to an average of $499.40 by 2050, and a maximum in that period of $1,040.75. This trajectory implies substantial upside potential, though the 2026 forecast indicates a neutral stance with a 0% ROI.
Overall, the forecast landscape suggests a bullish longer-term momentum, with annual averages advancing from the mid-to-high teens toward the several-hundred-dollar range by 2040 and beyond, accompanied by progressively higher maximums and strong historical volatility implied by the year-by-year figures.
These numbers provide a framework for evaluating price progression and risk, illustrating a potential multi-year upside while underscoring that these values are projections and not guarantees.
A major floor 39.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.7% below — buyers have tended to step in here.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 35.7% above — clearing it would confirm fresh momentum.
Key NGNE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NGNE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.25 | Sell | $27.39 | Sell |
| MA 10 | $28.48 | Sell | $28.00 | Sell |
| MA 20 | $28.91 | Sell | $28.01 | Sell |
| MA 50 | $25.10 | Buy | $25.99 | Buy |
| MA 100 | $22.14 | Buy | $24.06 | Buy |
| MA 200 | $22.45 | Buy | $22.96 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.72 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -70.58 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.66 | Sell |
| ROC (12) | -12.70 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 24.87 | Buy |
| Momentum (10) | -4.67 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 26.88 | Sell |
| ADX (14) | 18.18 | Neutral |
| ATR (14) | 0.83 | Info |
The 30-day technical picture shows a bullish tilt for the near term with a neutral-to-bullish balance reflected in a midline RSI around 50. The stock trades near the $27.71 area, with near-term momentum supported by a 50-day moving average near $24.88 and a 200-day moving average near $22.40.
Support is indicated at $19.28 and resistance at $32.62, framing a 30-day price range from $21.78 to $35.26. This setup suggests a trading band that could guide near-term price action, with volatility currently elevated at about 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.37 | $26.87 | $39.17 | 0% | Neutral | |
| $27.13 | $35.13 | $48.60 | +31% | Bullish | |
| $29.11 | $39.05 | $56.43 | +45% | Bullish | |
| $33.71 | $46.61 | $69.70 | +73% | Bullish | |
| $39.03 | $55.43 | $85.31 | +106% | Bullish | |
| $49.53 | $72.09 | $113.78 | +168% | Bullish | |
| $60.96 | $90.82 | $146.60 | +238% | Bullish | |
| $65.07 | $99.08 | $163.23 | +269% | Bullish | |
| $71.85 | $111.71 | $187.50 | +316% | Bullish | |
| $72.60 | $115.18 | $196.71 | +329% | Bullish | |
| $130.81 | $227.73 | $418.04 | +748% | Bullish | |
| $207.89 | $427.50 | $870.83 | +14.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.37 | $26.87 | $31.58 | +0.00% |
| June 2026 | $22.95 | $27.11 | $32.90 | +0.88% |
| July 2026 | $23.91 | $28.55 | $35.24 | +5.31% |
| August 2026 | $24.07 | $28.98 | $36.24 | +1.53% |
| September 2026 | $23.77 | $28.82 | $36.42 | -0.55% |
| October 2026 | $24.53 | $29.94 | $38.19 | +3.87% |
| November 2026 | $25.20 | $30.94 | $39.80 | +3.34% |
| December 2026 | $24.48 | $30.21 | $39.17 | -2.34% |
Click any year to see its month-by-month NGNE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NGNE to range from $16.37 to $39.17 through 2026. The $26.87 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NGNE price prediction for 2027 points to an average of $35.13 (low $27.13, high $48.60) — a potential gain of +31% on today's $26.87. Momentum favours further upside here.
In 2028, NGNE is projected to trade between $29.11 and $56.43, averaging $39.05 — a potential gain of +45% from today's $26.87. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Neurogene Inc.'s 2029 outlook centres on $46.61, within a $33.71 to $69.70 range. That is up +19% on the projected 2028 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2030, NGNE could reach as high as $85.31, with a base case around $55.43 and support toward $39.03 — roughly +106% from $26.87. Buyers look set to stay in control over this stretch.
Expect NGNE to range from $49.53 to $113.78 through 2031. The $72.09 average target implies a +168% move from current prices. That is up +30% on the projected 2030 average. Momentum favours further upside here.
The NGNE price prediction for 2032 points to an average of $90.82 (low $60.96, high $146.60) — a potential gain of +238% on today's $26.87. Buyers look set to stay in control over this stretch.
In 2033, NGNE is projected to trade between $65.07 and $163.23, averaging $99.08 — a potential gain of +269% from today's $26.87. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Neurogene Inc.'s 2034 outlook centres on $111.71, within a $71.85 to $187.50 range. That is up +13% on the projected 2033 average. That marks a +316% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NGNE could reach as high as $196.71, with a base case around $115.18 and support toward $72.60 — roughly +329% from $26.87. Momentum favours further upside here.
Expect NGNE to range from $130.81 to $418.04 through 2040. The $227.73 average target implies a +748% move from current prices. That is up +98% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NGNE price prediction for 2050 points to an average of $427.50 (low $207.89, high $870.83) — a potential gain of +14.9x on today's $26.87. Momentum favours further upside here.
Investing $1,000 in NGNE today (≈ 37.216226 NGNE) could be worth
$15,909.81
+$14,909.81 (+1491%) by 2050 · US Dollar
Based on the average projected NGNE price of $427.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NGNEwould be worth at today's price.
$1,000 invested in NGNE on May 27, 2025 (≈ 58.51375 NGNE) would be worth
$1,572.26
+$572.26 (+57.2%) today · 1.57× · US Dollar
Based on a NGNE entry price of $17.09 vs. today's $26.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $26.95 | $997.03 | -0.3% |
| 1 month ago | $27.05 | $993.35 | -0.7% |
| 3 months ago | $19.68 | $1,365.35 | +36.5% |
| 6 months ago | $21.08 | $1,274.67 | +27.5% |
| 1 year ago | $17.09 | $1,572.26 | +57.2% |
| All time (5.0y) ago | $196 | $137.09 | -86.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NGNE forecast.
Our base-case forecast reaches $54.00 around 2030.
Implied market cap at $54.00: $853.3M
Looking farther out, the multi-year forecast paints a clear path of rising averages and sizable upside. The 2026 forecast shows an average of $27.71 with a min of $16.37 and a max of $40.64, yielding a 0% ROI and a neutral sentiment. By 2027, the average climbs to $36.99 (min $28.36, max $51.65) with a 33.5% ROI and bullish sentiment, followed by 2028 at an average of $41.30 (min $30.49, max $60.34) and a 49% ROI.
The 2030 forecast projects an average of $60.86 (min $42.30, max $94.94) with a 119.6% ROI and bullish sentiment, continuing to 2040 with an average of $262.55 (min $146.64, max $491.49) and an 847.5% ROI. The long horizon culminates in 2050 with an average of $499.40 (min $232.60, max $1,040.75) and a 1702.3% ROI, still characterized as bullish.
These figures illustrate a strong upward trajectory in averages and potential upside, but they are estimates and not guarantees. Risks and uncertainties inherent in equity and biotechnology markets could lead to divergent results.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $60.86, with a min of $42.30 and a max of $94.94, and a ROI of 119.6% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with averages rising to $36.99 in 2027, $60.86 in 2030, and $499.40 in 2050, yielding ROIs up to 1702.3%, but these are estimates and not guarantees.
Yes. The 2050 forecast lists a max of $1,040.75.
Current price is $27.71 and market cap is $437.87M; the stock is ranked 3138.
The sentiment is BULLISH with RSI 14 at 50. The 50-day SMA is $24.88 and the 200-day SMA is $22.40. Support is at $19.28 and resistance at $32.62, with a 30-day range of $21.78 to $35.26 and volatility around 70%.
Neurogene Inc. Community Discussion
0Share your Neurogene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.